natgillin/translations-raw huggingface dataset:
Other serious side effects include a disorder related to white blood cells known as differentiation syndrome, a brain condition known as posterior reversible encephalopathy syndrome (PRES) and heart rhythm problems. 
Ostale ozbiljne nuspojave uključuju poremećaj povezan s bijelim krvnim stanicama poznat pod nazivom sindrom diferencijacije, oštećenje mozga poznato kao sindrom posteriorne reverzibilne encefalopatije (PRES) i problemi sa srčanim ritmom.
An overview of Xospata and why it is authorised in the EU 
Pregled informacija o lijeku Xospata i zašto je odobren u EU-u
AML is rare, and Xospata was designated an ‘orphan medicine' (a medicine used in rare diseases) on 17 January 2018. 
AML je rijetka bolest, a lijek Xospata dobio je status „lijeka za rijetku bolest” 17. siječnja 2018.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xospata have also been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Xospata također se nalaze u sažetku opisa svojstava i u uputi o lijeku.
The most common side effects with Xospata (which may affect more than 1 in 10 people) are increased levels of some enzymes in the blood (creatine phosphokinase, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase), diarrhoea, tiredness, nausea (feeling sick), constipation, cough, peripheral oedema (swelling, especially of the ankles and feet), dyspnoea (shortness of breath), dizziness, hypotension (low blood pressure), pain in the extremities, weakness, joint pain and muscle pain. 
Najčešće nuspojave povezane s lijekom Xospata (koje se mogu javiti u više od 1 na 10 osoba) jesu povišene vrijednosti određenih enzima u krvi (kreatin fosfokinaze, alanin aminotransferaze, aspartat aminotransferaze, alkalne fosfataze), proljev, umor, mučnina, konstipacija, kašalj, periferni edem (oticanje, posebno gležnjeva i stopala), dispneja (otežano disanje), omaglica, hipotenzija (nizak krvni tlak), bol u ektremitetima, iscrpljenost, bol u zglobovima i mišićima.
The active substance in Xospata is gilteritinib. 
Djelatna tvar lijeka Xospata je gilteritinib.
As for all medicines, data on the use of Xospata are continuously monitored. 
Kao i za sve lijekove, podatci o primjeni lijeka Xospata kontinuirano se prate.
Before starting treatment, doctors will use a genetic test to confirm that the patient has an FLT3 mutation. 
Prije početka liječenja liječnici će provesti genetsko testiranje kako bi potvrdili mutaciju gena FLT3 u bolesnika.
Xospata can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in using cancer medicines. 
Xospata se izdaje samo na recept, a liječenje treba započeti i nadzirati liječnik s iskustvom u primjeni lijekova protiv raka.
The most common serious side effects (which may affect up to 1 in 10 people) are diarrhoea, increased levels of liver enzymes in the blood, dyspnoea and hypotension. 
Najčešće ozbiljne nuspojave (koje se mogu javiti u najviše 1 na 10 osoba) jesu proljev, povišene vrijednosti jetrenih enzima u krvi, dispneja i hipotenzija.
Why is Xospata authorised in the EU? 
Zašto je lijek Xospata odobren u EU-u?
For more information about using Xospata, see the package leaflet or contact your doctor or pharmacist. 
Za više informacija o primjeni lijeka Xospata pročitajte uputu o lijeku, odnosno obratite se liječniku ili ljekarniku.
The active substance in Xospata, gilteritinib, blocks the action of enzymes known as tyrosine kinases, in particular a tyrosine kinase called FLT3 which normally controls growth and division of white blood cells. 
Djelatna tvar u lijeku Xospata, gilteritinib, blokira djelovanje enzima poznatih pod nazivom tirozin kinaze, osobito tirozin kinazu FLT3 koja uglavnom kontrolira rast i diobu bijelih krvnih stanica.
Xospata was shown to prolong patients' lives in comparison to other cancer therapies. 
Pokazalo se da lijek Xospata produljuje život bolesnika u usporedbi s drugim lijekovima protiv raka.
Xospata is a cancer medicine used to treat adults with acute myeloid leukaemia (AML), a cancer of white blood cells. 
Xospata je lijek protiv raka koji koristi za liječenje odraslih osoba s akutnom mijeloičnom leukemijom (ALM), vrstom raka bijelih krvnih stanica.
Side effects with Xospata are those expected of this class of medicines and considered manageable. 
Nuspojave lijeka Xospata očekivane su za ovaj razred lijekova i mogu se kontrolirati.
Patients with AML who have an FLT3 mutation, and whose disease has come back or has not improved following previous treatment, have a poor prognosis and treatment options are limited. 
Bolesnici s AML-om koji imaju mutaciju gena FLT3 i čija se bolest vratila ili se njihovo stanje nije poboljšalo nakon prethodne terapije, imaju lošu prognozu i ograničene mogućnosti liječenja.
In patients who have an FLT3 mutation, FLT3 is overactive and stimulates the growth of too many white blood cells. 
U bolesnika koji imaju mutaciju gena FLT3, gen FLT3 pretjerano je aktivan i potiče rast prevelikog broja bijelih krvnih stanica.
Further information on Xospata can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/xospata This overview was last updated in 10-2019. 
Više informacija o lijeku Xospata dostupno je na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/xospata
By blocking FLT3, gilteritinib is expected to stop white blood cell growth and thus slow down the development of the cancer. 
Blokiranjem gena FLT3 očekuje se da će gilteritinib zaustaviti rast bijelih krvnih stanica i usporiti razvoj raka.
Xospata is used when AML has either come back or has not improved following previous treatment and is only given to patients whose cancer cells have a particular change (mutation) in the gene for a protein called FLT3. 
Lijek Xospata koristi se kada se AML vratio ili se stanje bolesnika nije poboljšalo nakon prethodne terapije i daje se samo bolesnicima u čijim stanicama raka dolazi do promjene (mutacije) gena u pogledu proteina FLT3.
How does Xospata work? 
Kako djeluje Xospata?
In a main study with 371 patients with AML who have an FLT3 mutation, and whose disease had come back or had not improved following previous treatment, Xospata prolonged patients' lives compared with patients receiving chemotherapy. 
U glavnom ispitivanju na 371 bolesniku s AML-om koji imaju mutaciju gena FLT3 i čija se bolest vratila ili se njihovo stanje nije poboljšalo nakon prethodne terapije, Xospata je produljio život bolesnika u usporedbi s bolesnicima koji su primali kemoterapiju.
What benefits of Xospata have been shown in studies? 
Koje su koristi od lijeka Xospata utvrđene u ispitivanjima?
For the full list of side effects and restrictions of Xospata, see the package leaflet. 
Potpuni popis nuspojava i ograničenja povezanih s primjenom lijeka Xospata potražite u uputi o lijeku.
How is Xospata used? 
Kako se Xospata primjenjuje?
Xospata received a marketing authorisation valid throughout the EU on 24 October 2019. 
Pregled informacija posljednji je put ažuriran u 10. 2019.
Date of opening:__________ 
Datum otvaranja:___________
Do not give this medicine to children less than 12 years of age. 
Ovaj lijek se ne smije davati djeci mlađoj od 12 godina.
The tablet can be taken with or without food. 
Tableta se može uzeti s hranom ili bez nje.
If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule. 
Ako ste zaboravili uzeti svoju dozu lijeka na vrijeme, uzmite ju što je prije moguće, a zatim nastavite lijek uzimati prema uobičajenom rasporedu.
Other medicines and Dasselta 
Drugi lijekovi i Dasselta
7 film-coated tablets: EU/1/11/739/001 10 film-coated tablets: EU/1/11/739/002 20 film-coated tablets: EU/1/11/739/003 30 film-coated tablets: EU/1/11/739/004 50 film-coated tablets: EU/1/11/739/005 90 film-coated tablets: EU/1/11/739/006 100 film-coated tablets: EU/1/11/739/007 250 film-coated tablets: EU/1/11/739/008 
7 filmom obloženih tableta: EU/1/11/739/001 10 filmom obloženih tableta: EU/1/11/739/002 20 filmom obloženih tableta: EU/1/11/739/003 30 filmom obloženih tableta: EU/1/11/739/004 50 filmom obloženih tableta: EU/1/11/739/005 90 filmom obloženih tableta: EU/1/11/739/006 100 filmom obloženih tableta: EU/1/11/739/007 250 filmom obloženih tableta: EU/1/11/739/008
Date of first authorisation: 28 November 2011 Date of latest renewal: 16 August 2016 
Datum posljednje obnove odobrenja: 16. kolovoza 2016.
Shelf life after first opening of the tablet container: 3 months. 
Rok valjanosti nakon prvog otvaranja spremnika za tablete: 3 mjeseca.
Talk to your doctor or pharmacist before taking Dasselta: - if you have poor kidney function. 
Obratite se svom liječniku ili ljekarniku prije nego uzmete Dasseltu: - ako imate oslabljenu funkciju bubrega.
As a precautionary measure, it is preferable to avoid the use of desloratadine during pregnancy. 
Kao mjera opreza, preporučuje se izbjegavati primjenu desloratadina tijekom trudnoće.
The enzyme responsible for the metabolism of desloratadine has not been identified yet, and therefore, some interactions with other medicinal products can not be fully excluded. 
Enzim odgovoran za metabolizam desloratadina još nije utvrđen stoga se neke interakcije s drugim lijekovima ne mogu potpuno isključiti.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from desloratadine therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. 
Potrebno je odlučiti da li prekinuti dojenje ili prekinuti liječenje/suzdržati se od liječenja desloratadinom uzimajući u obzir korist dojenja za dijete i korist liječenja za ženu.
Pharmacotherapeutic group: Other antihistamines for systemic use, ATC code: R06AX27 
Farmakoterapijska skupina: Ostali antihistaminici za sustavnu primjenu, ATK oznaka: R06AX27
What Dasselta is and what it is used for 
Što je Dasselta i za što se koristi
- abnormal behaviour, - aggression, - weight increased, - increased appetite. 
- agresija - povećana tjelesna težina - povećan apetit.
Blister (OPA/Alu/PVC//Alu): 7, 10, 20, 30, 50, 90 and 100 film-coated tablets, in a box. 
Blister (OPA/Al/PVC//Al): 7, 10, 20, 30, 50, 90 i 100 filmom obloženih tableta, u kutiji.
If you take more Dasselta than you should 
Ako uzmete više Dasselte nego što ste trebali
Do not take Dasselta - if you are allergic to desloratadine, to any of the other ingredients of this medicine (listed in section 6) or to loratadine. 
Nemojte uzimati Dasseltu - ako ste alergični na desloratadin, neki drugi sastojak ovog lijeka (naveden u dijelu 6.) ili na loratadin.
Regarding the duration of treatment, your doctor will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Dasselta. 
Vezano za trajanje liječenja, Vaš će liječnik odrediti od kojeg tipa alergijskog rinitisa bolujete te koliko dugo trebate uzimati Dasseltu.
Very rare (the following may affect up to 1 in 10,000 people): - severe allergic reactions, - rash, - pounding or irregular heartbeat, - fast heartbeat, - stomach ache, - feeling sick (nausea), - vomiting, - upset stomach, - diarrhoea, - dizziness, - drowsiness, - inability to sleep, - muscle pain, - hallucinations, - seizures, - restlessness with increased body movement, - liver inflammation, - abnormal liver function tests. 
Vrlo rijetke (sljedeće nuspojave mogu se javiti u do 1 na 10 000 osoba) - teške alergijske reakcije - osip - lupanje ili nepravilni otkucaji srca - ubrzani otkucaji srca - bol u želucu - mučnina - povraćanje - želučane tegobe - proljev - omaglica - omamljenost - nesanica - bol u mišićima - halucinacije - napadaji - nemir s pojačanim kretnjama tijela - upala jetre - odstupanja od normalnih rezultata testova funkcije jetre.
What you need to know before you take Dasselta 
Što morate znati prije nego počnete uzimati Dasseltu
for tablet container: 
za spremnik za tablete:
The safety and efficacy of Dasselta 5 mg film-coated tablets in children below the age of 12 years have not been established. 
Sigurnost i djelotvornost lijeka Dasselta 5 mg filmom obložene tablete u djece mlađe od 12 godina nisu ustanovljene.
If you forget to take Dasselta 
Ako ste zaboravili uzeti Dasseltu
Dasselta with food, drink and alcohol Dasselta may be taken with or without a meal. 
Dasselta s hranom, pićem i alkoholom Dasselta se može uzeti uz ili bez obroka.
There is limited clinical trial efficacy experience with the use of desloratadine in adolescents 12 through 17 years of age (see sections 4.8 and 5.1). 
Postoji ograničeno iskustvo iz kliničkih ispitivanja djelotvornosti primjenom desloratadina u adolescenata u dobi od 12 do 17 godina (vidjeti dijelove 4.8 i 5.1).
Adults and adolescents 12 years of age and over The recommended dose is one tablet once a day with water, with or without food. 
Odrasli i adolescenti u dobi od 12 godina i stariji Preporučena doza je jedna tableta jedanput na dan, a uzima se s vodom, uz obrok ili natašte.
What Dasselta is and what it is used for What you need to know before you take Dasselta How to take Dasselta 
Što se nalazi u ovoj uputi Što je Dasselta i za što se koristi Što morate znati prije nego počnete uzimati Dasseltu Kako uzimati Dasseltu
Common (the following may affect up to 1 in 10 people): - fatigue, - dry mouth, - headache. 
Česte (sljedeće nuspojave mogu se javiti u do 1 na 10 osoba) - umor - suha usta - glavobolja
Not known: frequency cannot be estimated from the available data - slow heartbeat, - change in the way the heart beats, - abnormal behaviour, - aggression. 
Nepoznata učestalost: ne može se procijeniti iz dostupnih podataka - usporen rad srca - promjene u načinu otkucaja srca - neuobičajeno ponašanje - agresija.
For urticaria, the duration of treatment may be variable from patient to patient and therefore you should follow the instructions of your doctor. 
Trajanje liječenja urtikarije razlikuje se od bolesnika do bolesnika, stoga trebate slijediti upute svog liječnika.
There are no known interactions of Dasselta with other medicines. 
Nema poznatih interakcija između lijeka Dasselta i drugih lijekova.
An improvement in pruritus of more than 50 % was observed in 55 % of patients treated with desloratadine compared with 19 % of patients treated with placebo. 
Zabilježeno je smanjenje svrbeža za više od 50% u 55% bolesnika liječenih desloratadinom, u usporedbi s 19% bolesnika koji su primali placebo.
In the case of severe renal insufficiency, Dasselta should be used with caution (see section 5.2). 
U slučaju teške insuficijencije bubrega, Dasseltu treba oprezno primjenjivati (vidjeti dio 5.2).
Do not use this medicine after the expiry date which is stated on the packaging after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji iza oznake „EXP“.
Hypersensitivity to the active substance, to any of the excipients listed in section 6.1 or to loratadine. 
Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1 ili na loratadin.
Adults and adolescents (12 years of age and over) The recommended dose of Dasselta is one tablet once a day. 
Odrasli i adolescenti (u dobi od 12 godina i stariji) Preporučena doza lijeka Dasselta je jedna tableta jedanput na dan.
film-coated tablet for blister: 
filmom obložena tableta za blister:
Excipient with known effect: Each film-coated tablet contains 16.15 mg lactose (as monohydrate). 
Pomoćna tvar s poznatim učinkom: Jedna filmom obložena tableta sadrži 16,15 mg laktoze (u obliku hidrata).
Tablet container (HDPE, volume 60 ml), PP closure with desiccant: 250 film-coated tablets, in a box. 
Spremnik za tablete (HDPE, volumen 60 ml), plastični (PP) zatvarač sa sredstvom za sušenje: 250 filmom obloženih tableta, u kutiji.
Dasselta is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with: - allergic rhinitis (see section 5.1), - urticaria (see section 5.1). 
Dasselta je indicirana u odraslih i adolescenata u dobi od 12 ili više godina za ublažavanje simptoma povezanih s: - alergijskim rinitisom (vidjeti dio 5.1), - urtikarijom (vidjeti dio 5.1).
In two placebo-controlled six week trials in patients with chronic idiopathic urticaria, desloratadine was effective in relieving pruritus and decreasing the size and number of hives by the end of the first dosing interval. 
U dva placebom kontrolirana ispitivanja u trajanju od šest tjedana u bolesnika s kroničnom idiopatskom urtikarijom, desloratadin je učinkovito ublažavao svrbež i smanjivao veličinu i broj koprivnjača do kraja prvog intervala doziranja.
7 film-coated tablets 10 film-coated tablets 20 film-coated tablets 30 film-coated tablets 50 film-coated tablets 90 film-coated tablets 100 film-coated tablets for tablet container: 250 film-coated tablets 
7 filmom obloženih tableta 10 filmom obloženih tableta 20 filmom obloženih tableta 30 filmom obloženih tableta 50 filmom obloženih tableta 90 filmom obloženih tableta 100 filmom obloženih tableta za spremnik za tablete: 250 filmom obloženih tableta
During the marketing of desloratadine, cases of severe allergic reactions (difficulty in breathing, wheezing, itching, hives and swelling) have been reported very rarely. 
Nakon stavljanja desloratadina u promet, slučajevi teških alergijskih reakcija (otežano disanje, zviždanje pri disanju, svrbež, koprivnjača i oticanje) bili su prijavljeni vrlo rijetko.
Dasselta is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy). 
Dasselta se također koristi za ublažavanje simptoma povezanih s urtikarijom (promjene na koži uslijed alergije).
After oral administration, desloratadine selectively blocks peripheral histamine H1receptors because the substance is excluded from entry to the central nervous system. 
Nakon peroralne primjene, desloratadin selektivno blokira periferne histaminske H1-receptore budući da ne prodire u središnji živčani sustav.
In clinical studies with desloratadine, the following side effects were reported as: 
U kliničkim ispitivanjima s loratadinom, sljedeće nuspojave bile su prijavljene kao:
Dasselta relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older. 
Dasselta ublažava simptome povezane s alergijskim rinitisom (upala nosnih puteva uzrokovana alergijom, na primjer, kod peludne groznice ili alergije na grinje) u odraslih osoba i adolescenata u dobi od 12 ili više godina.
250 film-coated tablets 
250 filmom obloženih tableta
Each film-coated tablet contains 5 mg desloratadine. 
Jedna filmom obložena tableta sadrži 5 mg desloratadina.
Dasselta is available in carton boxes of 7, 10, 20, 30, 50, 90 and 100 film-coated tablets in blisters and in tablet container of 250 film-coated tablets. 
Dasselta je dostupna u kutijama od 7, 10, 20, 30, 50, 90 i 100 filmom obloženih tableta u blisterima te u spremniku za tablete koji sadrži 250 film obloženih tableta.
What Dasselta is Dasselta contains desloratadine which is an antihistamine. 
Što je Dasselta Dasselta sadrži desloratadin, koji je antihistaminik.
Dasselta is an antiallergy medicine that does not make you drowsy. 
Dasselta je lijek protiv alergije koji ne izaziva pospanost.
If your allergic rhinitis is intermittent (presence of symptoms for less than 4 days per week or for less than 4 weeks), your doctor will recommend you a treatment schedule that will depend on the evaluation of the history of your disease. 
Ako je Vaš alergijski rinitis intermitentni (simptomi su prisutni manje od 4 dana u tjednu ili manje od 4 tjedna), Vaš liječnik će Vam preporučiti raspored liječenja koji će ovisiti o procjeni Vaše povijesti bolesti.
Use caution when taking Dasselta with alcohol. 
Potreban je oprez kada se Dasselta uzima s alkoholom.
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with desloratadine were reported in 3 % of patients in excess of those treated with placebo. 
U kliničkim ispitivanjima kod različitih indikacija, uključujući alergijski rinitis i kroničnu idiopatsku urtikariju, pri preporučenoj dozi od 5 mg dnevno, kod primjene desloratadina zabilježene su nuspojave u 3% više bolesnika nego u onih koji su primali placebo.
Not known: frequency cannot be estimated from the available data - unusual weakness, - yellowing of the skin and/or eyes, - increased sensitivity of the skin to the sun, even in case of hazy sun, and to UV light, for instance to UV lights of a solarium, - changes in the way the heart beats, 
Nepoznate: učestalost se ne može procijeniti iz dostupnih podataka - neuobičajena slabost - žutilo kože i/ili očiju - povećana osjetljivost kože na sunčevu svjetlost, čak i u slučaju slabog sunca, i na UV
Light blue, round, film-coated tablets with beveled edges (diameter: 6.5 mm, thickness: 2.3-3.5 mm). 
Svijetlo plave, okrugle, filmom obložene tablete s ukošenim rubovima (promjera: 6,5 mm, debljine: 2,3-3,5 mm).
In a clinical pharmacology trial desloratadine tablets taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol (see section 5.1). 
U kliničkom farmakološkom ispitivanju, uzimanje tableta desloratadina istodobno s alkoholom nije pojačalo štetne učinke alkohola na ponašanje (vidjeti dio 5.1).
Fertility There is no data available on male/female fertility. 
Plodnost Nisu dostupni podaci o plodnosti u muškaraca/žena.
Other undesirable effects reported during the post-marketing period in paediatric patients with an unknown frequency included QT prolongation, arrhythmia, bradycardia, abnormal behaviour and aggression. 
Ostale nuspojave nepoznate učestalosti prijavljene u pedijatrijskih bolesnika nakon stavljanja lijeka u promet uključivale su produljenje QT intervala, aritmiju, bradikardiju, neuobičajeno ponašanje i agresiju.
Excipient: lactose monohydrate. 
Pomoćna tvar: laktoza hidrat.
As with other antihistamine trials in chronic idiopathic urticaria, the minority of patients who were identified as nonresponsive to antihistamines was excluded. 
Kao i kod drugih ispitivanja antihistaminika kod kronične idiopatske urtikarije, manji broj pacijenata, u kojih je utvrđeno da ne reagiraju na antihistaminike, bio je isključen iz ispitivanja.
Elevations of liver enzymes, increased bilirubin, hepatitis 
Poremećaji jetre i žuči vrlo rijetko nepoznato povećanje jetrenih enzima, povišeni bilirubin, hepatitis žutica
If you are pregnant or nursing a baby, taking Dasselta is not recommended. 
Ako ste trudni ili dojite, nije preporučljivo uzimati Dasseltu.
In clinical pharmacology trials, co-administration with alcohol did not increase the alcohol-induced impairment in performance or increase in sleepiness. 
U kliničkim farmakološkim ispitivanjima, istodobna primjena desloratadina i alkohola nije pojačala štetne učinke alkohola na ponašanje ili povećala pospanost.
In a single dose study performed in adults, desloratadine 5 mg did not affect standard measures of flight performance including exacerbation of subjective sleepiness or tasks related to flying. 
U ispitivanju učinka jednokratnih doza desloratadina od 5 mg u odraslih osoba, nije bilo utjecaja na standardna mjerila uspješnosti upravljanja letjelicama, uključujući i egzacerbaciju subjektivnog osjećaja pospanosti ili zadataka vezanih uz upravljanje letjelicama.
In patients with allergic rhinitis, desloratadine was effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate. 
U bolesnika s alergijskim rinitisom, desloratadin je bio učinkovit u ublažavanju simptoma kao što su kihanje, curenje i svrbež nosa, kao i svrbež, suzenje i crvenilo očiju te svrbež nepca.
How to take Dasselta 
Kako uzimati Dasseltu
What Dasselta contains - The active substance is desloratadine. 
Što Dasselta sadrži - Djelatna tvar je desloratadin.